| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 04/28/2005 | WO2005037858A2 Template-directed assembly of receptor signaling complexes |
| 04/28/2005 | WO2005037854A2 Immunogenic peptides |
| 04/28/2005 | WO2005037392A2 Method for the dissociation of the extracellular haemoglobin molecule of arenicola marina and the characterisation of the protein chains forming the molecule and the nucleotide sequences coding for said protein chains |
| 04/28/2005 | WO2005037322A1 Oncogene therapeutic drug |
| 04/28/2005 | WO2005037321A1 Oncogene therapeutic drug |
| 04/28/2005 | WO2005037311A1 Pharmaceutical compositions for therapeutic use |
| 04/28/2005 | WO2005037305A1 Therapeutic uses of chemokine variants |
| 04/28/2005 | WO2005037303A1 Methods and compositions of ig20 and denn-sv splice variants |
| 04/28/2005 | WO2005037301A1 Treatment of cognitive dysfunction un lupus |
| 04/28/2005 | WO2005037297A1 Compositions and methods for inhibiting cell senescence and hyperproliferative disorders |
| 04/28/2005 | WO2005037229A2 Methods and compositions for modulating gamete adhesion |
| 04/28/2005 | WO2005037226A2 Genetically engineered enteroendocrine cells for treating glucose-related metabolic disorders |
| 04/28/2005 | WO2005037221A2 Cystatin c as an antagonist of tgf-b and methods related thereto |
| 04/28/2005 | WO2005037218A2 Lentiviral vector delivery of il-21 for treatment of cancer |
| 04/28/2005 | WO2005037210A2 Photocleavable isotope-coded affinity tags |
| 04/28/2005 | WO2005037191A2 Expression of dominant negative transmembrane receptors in the milk of transgenic animals |
| 04/28/2005 | WO2005037190A2 Multiplex vaccines |
| 04/28/2005 | WO2005037108A2 Compositions and devices including same useful for anastomosis |
| 04/28/2005 | WO2005037083A2 Mn/ca ix and cancer prognosis |
| 04/28/2005 | WO2005026204A3 Synthetic antimicrobial polypeptides |
| 04/28/2005 | WO2005024039A3 Improved method for generating influenza viruses and vaccines |
| 04/28/2005 | WO2005023300A3 Method for treating, preventing and/or diagnosing cancer, related to the use of mal2 polypeptide |
| 04/28/2005 | WO2005018682A3 Somatostatin analogs with inhibitory activity to growth hormone release |
| 04/28/2005 | WO2005013889A3 Truncated fragments of alpha-synuclein in lewy body disease |
| 04/28/2005 | WO2005012348A3 Cyclic cadherin analogues comprising the sequence hav for modulating the migration of vascular smooth muscle cells |
| 04/28/2005 | WO2005010165A3 Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof |
| 04/28/2005 | WO2005007811A3 Injection of bone marrow-derived cells and medium for angiogenesis |
| 04/28/2005 | WO2005007688A3 Human prostaglandin fp receptor variants and methods of using same |
| 04/28/2005 | WO2005003292A3 Composition and method for self-assembly and mineralization of peptide amphiphiles |
| 04/28/2005 | WO2005003161A3 Human secreted proteins |
| 04/28/2005 | WO2005001062A3 Modified vectors for organelle transfection |
| 04/28/2005 | WO2004113511A3 Cell line and uses thereof |
| 04/28/2005 | WO2004112820A3 Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity |
| 04/28/2005 | WO2004112570A3 Detection of survivin in the biological fluids of cancer patients |
| 04/28/2005 | WO2004110390A3 Anti-cd74 immunoconjugates and methods |
| 04/28/2005 | WO2004106917A3 Method for the selection of epitopes for immunotherapy |
| 04/28/2005 | WO2004104020A3 Repeat sequence protein polymer active agent conjugates, methods and uses |
| 04/28/2005 | WO2004098492A3 Trans-golgi network-associated processes, methods and compositions related thereto |
| 04/28/2005 | WO2004096832A3 Novel antiangiogenic peptides |
| 04/28/2005 | WO2004093530A3 Generation of plants with altered oil content |
| 04/28/2005 | WO2004093529A3 Generation of plants with altered oil content |
| 04/28/2005 | WO2004090135A3 Cytokine polypeptides and antibodies containing a signal sequence for the attachement of glycosylphosphatidylinositol |
| 04/28/2005 | WO2004078775A3 Intracellular signaling-induced ret-independent gdnf receptor-effected morphological changes |
| 04/28/2005 | WO2004075988A3 Methods of immunomodulation in animals |
| 04/28/2005 | WO2004064784A3 Composition and method for preventing or treating a virus infection |
| 04/28/2005 | WO2004048537A3 Lamps as modifiers of the p53 pathway and methods of use |
| 04/28/2005 | WO2004044160A3 Muc1 interference rna compositions and methods derived therefrom |
| 04/28/2005 | WO2004035746A3 Susceptibility gene for myocardial infarction |
| 04/28/2005 | WO2004033631A8 Nucleic acid and polypeptide sequences from lawsonia intracellularis and methods of using |
| 04/28/2005 | WO2004032839A3 Methods and formulations comprising agonists and antagonists of nuclear hormone receptors |
| 04/28/2005 | WO2004029224A3 Methods of engineering spatially conserved motifs in polypeptides |
| 04/28/2005 | WO2004022589A9 Tumor tag and the use thereof |
| 04/28/2005 | WO2004020583A8 Polynucleotide predictor set for identifying protein tyrosine kinase modulators |
| 04/28/2005 | WO2004011620A3 Methods and compositions using polynucleotides and polypeptides of rank-associated inhibitor (rain) |
| 04/28/2005 | WO2004003161A3 Immunogenic mycoplasma hyopneumoniae polypeptides |
| 04/28/2005 | WO2003100076A3 Pna probes, probe sets, method and kits pertaining to the determination of listeria |
| 04/28/2005 | WO2003099201A3 Compositions and methods of use for a fibroblast growth factor |
| 04/28/2005 | WO2003086276A3 Compositions and methods for portal specific gene delivery and treatment of infection |
| 04/28/2005 | WO2003084987A3 Polypeptides from bacteria and uses thereof |
| 04/28/2005 | US20050091717 transgenic plant comprising in its genome a transgene encoding a member FLC gene family; flowering locus C family genes; having early timing of its flowering |
| 04/28/2005 | US20050091714 Methods for obtaining nucleotide sequences coding for polypeptides specifically active for larvae of S. littoralis |
| 04/28/2005 | US20050091713 Nucleic acid nematicides |
| 04/28/2005 | US20050091711 isolated by identifying and analyzing genes of Arabidopsis thaliana; trichome is involved in secretion and excretion from the surface of a plant body |
| 04/28/2005 | US20050091709 Transgenic organism epressing fungal mrp-like abc transporters |
| 04/28/2005 | US20050091708 Nucleic acid compositions conferring altered metabolic characteristics |
| 04/28/2005 | US20050091704 transgenic mouse in which the Ant2 gene is inactivated in the liver; thought to be an integral component of the mitochondrial permeability transition pore |
| 04/28/2005 | US20050091703 Nonhuman model animal of th2-mediated hyperimmune response |
| 04/28/2005 | US20050091702 Expression of polypeptides in rod outer segment membranes |
| 04/28/2005 | US20050090658 Comprises polymorphic variations/point mutations linked to cation channel dysfunctions; genetic engineering; treansgenic animal; antibody |
| 04/28/2005 | US20050090652 Highly homogenous serum albumin as chiral selector |
| 04/28/2005 | US20050090651 Polymeric compounds |
| 04/28/2005 | US20050090649 synthetic metalloproteins; either covalent or non-covalent, with biomolecules such as antibodies, antigens, enzymes, receptors, nucleic acids, peptides and proteins |
| 04/28/2005 | US20050090647 Pharmaceutical compositions for treating arthritis and inflammatory disease |
| 04/28/2005 | US20050090646 cytotoxic fusion proteins that are useful for selectively killing endothelial cells in blood vessels that feed tumors |
| 04/28/2005 | US20050090643 protein isolated from cyanobacteria, is known to have anti-viral activity |
| 04/28/2005 | US20050090642 Genetically engineered protein for use as diagnostic tool in gentic analysis; isolated DNA, vector and transformant comprising said DNA; from Fungia sp |
| 04/28/2005 | US20050090641 miniblock polymers that can self-assemble into three-dimensional materials through liquid crystalline behavior |
| 04/28/2005 | US20050090448 Peptides that inhibit complement activation |
| 04/28/2005 | US20050090447 Peptides that promote complement activation |
| 04/28/2005 | US20050090445 Truncated keratinocyte growth factor (KGF) having increased biological activity |
| 04/28/2005 | US20050090442 administering peptides, polypeptides, proteins or mimetics which correspond to non-membrane associated form of the p75 neurotrophin receptor (p75NTR) death signal region; antiapoptosis |
| 04/28/2005 | US20050090441 inducing prolonged in vivo gene expression in mammal by contacting nonmuscular tissue with a nucleic acid, a histone, and an amphipathic compound; animal models: |
| 04/28/2005 | US20050090440 Tumour treating combinations, compositions and methods |
| 04/28/2005 | US20050090439 Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases |
| 04/28/2005 | US20050090438 Product and methods for diagnosis and therapy for cardiac and skeletal muscle disorders |
| 04/28/2005 | US20050090437 Ion channel modulators |
| 04/28/2005 | US20050090436 Human tumor necrosis factor receptors TR21 and TR22 |
| 04/28/2005 | US20050090435 nucleotide sequences, genetic vectors comprising and/or genes expressing the nucleotide sequences, use to transform plant cells to produce proteins or fragments of proteins used as anticarcinogenic agents |
| 04/28/2005 | US20050090434 Novel therapeutic targets in cancer |
| 04/28/2005 | US20050090430 treating hemachromatosis comprising administering an HFE polypeptide, fragments, or a complex with beta -2-microglobulin; genetic disorders |
| 04/28/2005 | US20050090429 Photo-active backbone cyclized somatostatin analogs for photodynamic therapy and imaging |
| 04/28/2005 | US20050090007 To produce human proteins in economical yields and in a form which is suitable for the production of a pharmaceutical preparation |
| 04/28/2005 | US20050090006 Nucleic acid molecules which modulate transcription of operably-linked sequences in Schwann cells |
| 04/28/2005 | US20050090003 Genetically-modified, non-human mammal, wherein the genome of the mammal comprises a genetic modification to a copy of the P2x7R gene that results in disrupted P2x7R gene function from the modified gene |
| 04/28/2005 | US20050090000 Novel human 7TM protein and polynucleotides encoding the same |
| 04/28/2005 | US20050089999 Method for the production and purification of adenoviral vectors |
| 04/28/2005 | US20050089988 polypeptides and nucleic acid sequences; utilizing such polypeptides to screen for antibacterial or bacteriostatic compound |
| 04/28/2005 | US20050089985 Rescue of canine distemper virus from cdna |
| 04/28/2005 | US20050089984 Having a specific amino acid sequence, especially fused to a heterologous polypeptide; induces apoptosis |
| 04/28/2005 | US20050089983 Novel protein, genes encoding the same and method of using the same |